Zelavespib
- Generic Name
- Zelavespib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21IN6O2S
- CAS Number
- 873436-91-0
- Unique Ingredient Identifier
- 06IVK87M04
- Background
Zelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).
A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Samus Therapeutics, Inc.
- Registration Number
- NCT05612633
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
- Conditions
- Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03935555
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae), Larkspur, California, United States
🇺🇸MD Anderson, Houston, Texas, United States
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- Conditions
- Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisMyelofibrosis
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03373877
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT03166085
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01581541
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
- Conditions
- Metastatic Solid TumorLymphomaMyeloproliferative Neoplasms (MPN)
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01393509
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.